Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities

Journal of Virology

Volumn 85, Issue 20, 2011, Pages 10730-10740

  Krachmarov, Chavdar ^a   Lai, Zhong ^a   Honnen, William J ^a   Salomon, Aidy ^a   Gorny, Miroslaw K ^c   Zolla Pazner, Susan ^c,d   Robinson, James ^b   Pinter, Abraham ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; GENE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN QUATERNARY STRUCTURE; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; EPITOPE MAPPING; EPITOPES; GENETIC VARIATION; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HUMANS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS;

MACACA MULATTA;

EID: 80054988972     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00365-11     Document Type: Article

References (44)

1. Back, N. K., et al. 1994. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199:431-438.
2. Cavacini, L., et al. 2003. Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base. AIDS 17:685-689.
3. Changela, A., et al. 2011. Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J. Virol. 85:2524-2535.
4. Connor, R., B. K. Chen, S. Choe, and N. R. Landau. 1995. Vpr is required for efficient replication of human immunodeficiency virus type 1 in mononuclear phagocytes. Virology 206.
5. Davenport, T. M., et al. 2011. Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific MAbs PG9 and PG16. J. Virol. 85:7095-7107.
6. Doores, K. J., and D. R. Burton. 2010. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 84:10510-10521.
7. Go, E. P., et al. 2008. Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J. Proteome Res. 7:1660-1674.
8. Gorny, M., et al. 2006. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from cells of individuals infected with non-B clades of human immunodeficiency virus type 1. J. Virol. 80:6865-6872.
9. Gorny, M. K., et al. 1992. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
10. Gorny, M. K., et al. 2005. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 79:5232-5237.
11. He, Y., et al. 2002. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. J. Immunol. 169:595-605.
12. Honnen, W. J., et al. 2007. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J. Virol. 81:1424-1432.
13. Hu, Q., et al. 2000. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. J. Mol. Biol. 302:359-375.
14. Kimura, T., X. H. Wang, C. Williams, S. Zolla-Pazner, and M. K. Gorny. 2009. Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins. Hum. Antibodies 18: 35-40.
15. Korber, B. T. M., et al. 2011. HIV sequence database compendia. Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, NM. http://www.hiv.lanl.gov/content/sequence/HIV/COMPENDIUM/compendium.html.
16. Krachmarov, C. P., et al. 2006. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J. Virol. 80:7127-7135.
17. Krachmarov, C. P., S. C. Kayman, W. J. Honnen, O. Trochev, and A. Pinter. 2001. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17:1737-1748.
18. Li, Y., M. A. Rey-Cuille, and S. L. Hu. 2001. N-linked glycosylation in the V3 region of HIV type 1 surface antigen modulates coreceptor usage in viral infection. AIDS Res. Hum. Retroviruses 17:1473-1479.
19. Ly, A., and L. Stamatatos. 2000. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J. Virol. 74:6769-6776.
20. Lynch, R. M., et al. 2011. The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J. Virol. 85:905-915.
21. McCaffrey, R. A., C. Saunders, M. Hensel, and L. Stamatatos. 2004. Nlinked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J. Virol. 78:3279-3295.
22. Moore, P. L., et al. 2011. Potent and broad neutralization of HIV-1 subtype C viruses by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J. Virol. doi:10.1128/JVI.02658-10.
23. Ogert, R. A., et al. 2001. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. J. Virol. 75:5998-6006.
24. O'Rourke, S. M., et al. 2010. Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J. Virol. 84:11200-11209.
25. Pancera, M., et al. 2010. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternaryspecific antibodies that effectively neutralize HIV-1. J. Virol. 84:8098-8110.
26. Pejchal, R., et al. 2010. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc. Natl. Acad. Sci. U. S. A. 107:11483-11488.
27. Pinter, A. 2007. Roles of HIV-1 Env variable regions in viral neutralization and vaccine development. Curr. HIV Res. 5:542-553.
28. Pinter, A., et al. 2004. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 78:5205-5215.
29. Pinter, A., W. J. Honnen, M. E. Racho, and S. A. Tilley. 1993. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates. AIDS Res. Hum. Retroviruses 9:985-996.
30. Pollakis, G., et al. 2001. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J. Biol. Chem. 276:13433-13441.
31. Polzer, S., M. T. Dittmar, H. Schmitz, and M. Schreiber. 2002. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 304: 70-80.
32. Polzer, S., H. Muller, and M. Schreiber. 2009. Effects of mutations on HIV-1 infectivity and neutralization involving the conserved NNNT amino acid sequence in the gp120 V3 loop. FEBS Lett. 583:1201-1206.
33. Purtscher, M., et al. 1994. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 10:1651-1658.
34. SF162P4. J. Virol. 84:3443-3453.
35. Schonning, K., B. Jansson, S. Olofsson, and J. E. Hansen. 1996. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. J. Gen. Virol. 77:753-758.
36. Schonning, K., B. Jansson, S. Olofsson, J. O. Nielsen, and J. S. Hansen. 1996. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology 218:134-140.
37. Shibata, J., et al. 2007. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. J. Virol. 81:3757-3768.
38. Stiegler, G., et al. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17:1757-1765.
39. Tilley, S. A., W. J. Honnen, M. E. Racho, T. C. Chou, and A. Pinter. 1992. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res. Hum. Retroviruses 8:461-467.
40. Walker, L. M., et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
41. Walker, L. M., et al. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6:1-14.
42. Wolk, T., and M. Schreiber. 2006. N-glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization. Med. Microbiol. Immunol. 195:165-172.
43. Wu, X., et al. 2011. Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. J. Virol. 85:4578-4585.
44. Wu, Z., et al. 1995. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. J. Virol. 69:2271-2278.